FP530

FP530 is an orally bioavailable small-molecule antibiotic candidate, also known as Formibactin A, being developed by Flightpath Biosciences as a narrow-spectrum peptide deformylase inhibitor targeting infection-associated diseases, with an initial focus on neuroborreliosis and other Lyme disease manifestations caused by Borrelia burgdorferi.[1][3][7][9] As a peptide deformylase inhibitor, FP530 blocks the essential bacterial enzyme responsible for removing the N-formyl group from nascent polypeptides, a key step in bacterial protein maturation, thereby exerting potent bactericidal activity while aiming to spare the commensal microbiome.[1][3][9] Rediscovered and characterized by Kim Lewis and collaborators, FP530 represents part of Flightpath’s strategy to develop microbiome-sparing therapeutics for chronic, infection-driven conditions.[3][5][7][9]

Other names

Formibactin A